Howard M. Sandler – författare

Urological oncology is a subject of enormous interest to large numbers of uro- gists throughout the world, particularly with our increasing understanding of the possible causes and pathogenesis of the condition. As Editor-in-Chief of one of the urological journals, I can attest to this interest; the largest percentage of the papers I receive for review each year relate to either clinical or experime- tal urological oncology. It used to be that the manuscripts concerned mainly surgical techniques, but now this has extended to new technologies, dia- nostic methods, randomized pharmaceutical clinical trials, and thoughtful and complex experimental studies into the genesis of urological cancer. This is all evidence of our increasing interest in the topic. In addition to this, we have come to understand the management of urolo- cal cancer is not in the hands of a single discipline. The advent of multidis- plinary team meetings has made us realize that there is a hugely signi? cant role to be played by urologists, medical oncologists, radiation oncologists, patho- gists, and radiologists. This new dimension has been driven by the advent of new therapies and by closer interaction among all of these groups at academic meetings. This is to be applauded and has inevitably lead to improvements in the management of our patients.